Aclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York
September 20 2017 - 8:00AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led,
biopharmaceutical company focused on identifying, developing and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, today
announced that Aclaris will host an R&D and Investor Event on
Wednesday, October 4, 2017, in New York from 8:00 AM – 12:00 PM.
Breakfast and lunch will be served.
A live and archived webcast of the event can be accessed on the
Events and Presentations page on the Investors section of the
Aclaris website at http://www.aclaristx.com/events-and-webcasts. A
replay of the webcast will be archived on the Aclaris website
following the event. If you are a member of the investment
community and would like to attend, please RSVP to
mtung@aclaristx.com. The agenda will include:
Commercial Update
- Brett Fair – Senior Vice President, Commercial Operations
- Sheila Kennedy – Vice President, Marketing
- John Bagdasarian – Vice President, Professional Relations
- Erika Dunbar – Director, Marketing
KOL Discussion on Seborrheic Keratosis and
Warts
- Adam Friedman, MD, FAAD - is an Associate Professor of
Dermatology and serves as Residency Program Director, Director of
Translational Research, and Director of the Supportive
Oncodermatology Program in the Department of Dermatology at The
George Washington University School of Medicine & Health
Sciences.
- Michael Gold, MD, FAAD - is the founder and medical director of
Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser
& Rejuvenation Center, and Tennessee Clinical Research Center
in Nashville, TN.
Genetics and Immunology of Alopecia Areata
- Angela M. Christiano, Ph.D., FACMG - is the Richard and Mildred
Rhodebeck Professor of Dermatology and Professor of Genetics and
Development at Columbia University Medical Center (CUMC). She is
also the Director of Research in the Department of Dermatology at
CUMC.
Immuno-Dermatology Pipeline Review (Former Confluence
Team)
- Walter Smith - has over 35 years of experience in leading
pharmaceutical research and development. Formerly the Vice
President and Global Head of Pfizer Inflammation/Immunology
Research Therapeutic Areas, Mr. Smith had portfolio responsibility
from discovery through commercialization.
- Joe Monahan, Ph.D. - has over 30 years of biochemical
pharmacology and drug discovery experience. Formerly an Executive
Director in the Pfizer Inflammation Research Unit, Dr. Monahan
directed numerous drug discovery programs into Phase 1 and 2 stages
of clinical development, and while at Pfizer he led the global
kinase technology platform.
- Jon Jacobsen, Ph.D. - has over 30 years of medicinal chemistry
and drug discovery experience. Formerly a senior scientist and
Director in the Pfizer Chemistry Department, he has directed
chemistry and project teams to provide Phase 1 candidates and has
also served on discovery teams for compounds in Phase 1 and 2
stages of development.
- Paul Changelian, Ph.D. - has over 25 years of experience in
drug discovery. His work focused on several areas, including renal
transplantation, autoimmune disease, mitochondrial metabolism and
oncology. He identified the JAK kinases as potential drug targets
and during his 18 years at Pfizer, his laboratory was responsible
for the preclinical candidate delivery and development of
tofacitinib in rheumatoid arthritis, psoriasis, IBD and renal
transplant.
About Aclaris Therapeutics, Inc.Aclaris
Therapeutics, Inc. is a dermatologist-led biopharmaceutical company
focused on identifying, developing and commercializing innovative
and differentiated therapies to address significant unmet needs in
medical and aesthetic dermatology. Aclaris is focused on
large, underserved market segments with no FDA-approved medications
or where treatment gaps exist. Aclaris is based in Malvern,
Pennsylvania and more information can be found by visiting the
Aclaris website at www.aclaristx.com.
Aclaris ContactMichael Tung, M.D.Investor
Relations484-329-2140mtung@aclaristx.com
Media ContactMariann
CaprinoTogoRun917-242-1087M.Caprino@togorun.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024